Overview
- Anvisa approved registration via Resolução-RE nº 1.041, granting Eli Lilly do Brasil permission to commercialize Mounjaro Multidose.
- The new presentation enables multiple injections from a single pen, replacing the traditional single-use device.
- The authorization covers six subcutaneous strengths—4.17, 8.33, 12.5, 16.7, 20.8 and 25 mg/mL—under a 24-month registration.
- Tirzepatide acts on hormones that regulate glucose and appetite, supporting treatment of type 2 diabetes and contributing to weight reduction.
- Pharmacy rollout depends on company steps such as price setting and launch strategy, and dispensing remains restricted to medical prescription.